Medical Licensing (MD/DO) · Independent exam preparation
FRCPath: Cross-Specialty Foundations Guide Study Guide
Practise biomarker interpretation, blood-film reasoning, biochemical analysis and infection testing through 60 focused concepts across five FRCPath specialties.
By CertMedbry · Updated 18 October 2026
Interpret discordant laboratory results, recognise diagnostic limitations and choose defensible next investigations. These 60 selective concepts develop reasoning across histopathology, haematology, clinical biochemistry, infection, and immunology and allergy. The framework is Fellowship by examination, comprising Parts 1 and 2 within a chosen specialty. The College's official specialty curriculum and examination outline define the full scope; this cross-specialty foundation guide samples that scope and cannot provide complete preparation for an individual specialty.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which qualification and pathway does this guide address?
It addresses the Fellowship examination of The Royal College of Pathologists, through the examination route involving Parts 1 and 2 in a chosen specialty. This guide provides cross-specialty foundations because no individual specialty or part is specified. It does not create a combined FRCPath examination. The 2026 handbook states that FRCPath alone grants no authority for unsupervised clinical practice; UK professional registration requirements remain separate.
Fellowship, Diploma and Certificate examinations: regulations and guidelines for 2026
Which regulations and blueprint dates apply?
The general regulations are the 2026 edition, issued December 2025 and superseding previous editions. The specialty regulations cited here are the currently linked 2026 editions; no separate specialty effective day is established. Histopathology's August 2021 curriculum reference and infection's autumn 2016 introduction describe historical curriculum or examination milestones, not new 2026 effective dates. Candidates must read both the general regulations and their specialty regulations.
Fellowship, Diploma and Certificate examinations: regulations and guidelines for 2026 · Histopathology examination regulations 2026 · Infection
What are the verified Part 1 question counts, durations and item styles?
Histopathology has 125 SBA/EMQ questions over three hours. Clinical biochemistry has 125 SBAs over three hours. Infection has two three-hour papers, each containing 100 SBAs. Haematology comprises two three-hour papers: an essay paper with four compulsory essays and an MCQ paper containing 50 best-from-five and 75 extended-matching questions. Immunology and allergy Part 1 comprises two three-hour short-answer papers. These formats belong to their individual specialties.
Histopathology examination regulations 2026 · Clinical biochemistry examination regulations 2026 · FRCPath Part 1 and Combined Infection Certificate Examination (CICE) regulations 2026 · Haematology examination regulations 2026 · Immunology and allergy examination regulations 2026
Are scored questions, pretest questions, delivery and adaptivity specified?
The cited regulations do not identify a scored-versus-pretest question split or describe adaptive testing. The 2026 handbook identifies Part 1 delivery through TestReach and describes live proctoring for online examinations. It also retains generic paper-based wording in its SBA/EMQ marking section, so session-specific College instructions should resolve operational details. Part 2 delivery and components depend on specialty. This guide's four-option questions are independent learning drills.
Fellowship, Diploma and Certificate examinations: regulations and guidelines for 2026
How do Part 1 and Part 2 differ?
Part 1 assesses underpinning specialty knowledge; Part 2 largely assesses practical application. Histopathology Part 2 includes surgical histology, non-gynaecological cytopathology, OSPE, macros, frozen sections and long cases; autopsy and gynaecological cytology are excluded from that Part 2 examination. Haematology includes morphology, coagulation and transfusion interpretation, and oral assessment. Clinical biochemistry includes practical and clinical/scientific/management modules. Four-option drills cannot reproduce those practical, oral, essay or short-answer assessments.
Fellowship, Diploma and Certificate examinations: regulations and guidelines for 2026 · Histopathology examination regulations 2026 · Haematology examination regulations 2026 · Clinical biochemistry examination regulations 2026
Are CICE and ACICE interchangeable with the Fellowship pathway?
No. Infection's shared Part 1 assessment also serves the Combined Infection Certificate Examination, but CICE is a distinct certificate outcome. Subsequent Fellowship Part 2 may be in medical microbiology or virology. In immunology and allergy, the ACLI pathway takes FRCPath Parts 1 and 2; the ACI pathway uses ACICE and does not take Part 2. This guide uses the Fellowship examination framework and does not substitute either certificate pathway.
FRCPath Part 1 and Combined Infection Certificate Examination (CICE) regulations 2026 · Immunology and allergy examination regulations 2026
How should published percentages influence preparation?
No official percentages allocate questions across these five specialties. This guide therefore uses 12 concepts, four questions and four flashcards per branch as an editorial allocation. Within infection alone, approximate proportions are basic science 10%, laboratory practice 15%, health and safety 2.5%, public health 5%, infection prevention/control 5%, clinical syndromes 32.5%, antimicrobials 15%, vaccination 5%, HIV 5% and travel medicine 5%. Clinical biochemistry's approximately 25% knowledge and 75% application describes cognitive demand, not specialty weights. The small infection selection here cannot reproduce its full topic distribution.
Infection · Clinical Biochemistry · Fellowship, Diploma and Certificate examinations: regulations and guidelines for 2026
Is there a universal passing score or fee?
There is no universal numerical passing score established for these specialty assessments. The handbook describes paper-specific standard setting, including modified Angoff methods for SBA/EMQ and short-answer papers, and specialty-dependent practical requirements. Its essay marking provisions should not be transferred to every examination format. Current fees are published separately by the College. Performance on these 20 learning questions does not predict a Fellowship examination result.
Fellowship, Diploma and Certificate examinations: regulations and guidelines for 2026
How should international candidates use the clinical references?
The College states that its examinations are oriented towards UK practice and the relevant UK curriculum, including for candidates outside the UK. The clinical references here support specific scientific principles and interpretation. Their local reporting conventions or service arrangements do not establish UK examination policy. Use the current specialty curriculum and applicable UK guidance to complete preparation beyond this selective guide.
Fellowship, Diploma and Certificate examinations: regulations and guidelines for 2026
An independently authored free guide with 20 learning questions and 20 recall cards. The five branches receive equal editorial coverage because the College publishes no combined specialty weighting. Clinical references support the scientific interpretations; College documents establish examination identity and scope.
Outline used: Verified against the College's 2026 general examination regulations, issued December 2025, and currently linked 2026 specialty regulations. The workbook label 'Fellowship of the Royal College of Pathologists (FRCPath)' names the Fellowship qualification; it maps to the College's specialty-specific Fellowship examination, comprising Parts 1 and 2. No specialty or examination part was assigned. This material therefore provides an explicitly limited cross-specialty preview using verified histopathology, haematology, clinical biochemistry, infection, and immunology/allergy outlines. It is not a combined official syllabus, a specialty mock examination, or a replacement credential.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Histopathologynot stated
1.How do tumour grade and anatomical stage answer different questions?
Grade describes microscopic characteristics associated with biological behaviour, such as differentiation and proliferative activity, using a tumour-specific system. Stage describes the anatomical extent of cancer. A small, localised tumour can therefore be high grade, while a well-differentiated tumour can already have distant metastases. Interpret each independently and name the relevant classification. The discriminating clue is whether the information concerns cellular appearance or where disease has spread.
Apply it
A resection shows a poorly differentiated carcinoma confined to the primary organ, with sampled nodes free of tumour. Explain that poor differentiation affects grade, whereas confinement and nodal findings inform anatomical stage.
Common pitfall: Calling a tumour advanced stage solely because it looks aggressive confuses microscopic biology with anatomical distribution and can produce an incorrect clinical summary.
2.Which disease findings belong to the T, N and M categories?
In TNM staging, T describes the primary tumour's size or local extent, N describes regional lymph-node involvement, and M describes distant metastasis. The precise definitions depend on tumour site and staging edition. Direct extension into an adjacent structure contributes to local extent rather than automatically establishing distant disease. Before assigning a category, distinguish regional from non-regional nodes and identify whether the evidence is clinical, imaging-based or pathological.
Apply it
A report describes invasion into adjacent tissue, tumour in a regional node and a separate confirmed liver metastasis. Organise these findings under primary tumour extent, regional nodal disease and distant metastatic disease respectively.
Common pitfall: Treating every involved node as distant metastasis ignores site-specific regional drainage definitions; TNM category thresholds cannot be transferred unchanged between different tumour types.
3.How should macroscopy preserve the information needed to assess excision margins?
Record specimen orientation, three-dimensional measurements, lesion dimensions and its relationship to peripheral and deep margins. Preserve the orientation with a block map and, where appropriate, distinguish margins using coloured inks. Select sections that demonstrate the lesion's closest approach to the relevant margins rather than sampling only its centre. Heterogeneous lesions need sampling of their different appearances. These principles are described in the College's [skin tissue pathway](https://www.rcpath.org/asset/88BFEEAF-7B1C-458E-BE2019C1324CD7AC/).
Apply it
An oriented skin ellipse contains a lesion close to one peripheral edge. Document that edge, ink the relevant surfaces and take mapped sections showing the lesion's closest peripheral and deep margins.
Common pitfall: A clear margin in an arbitrary central section cannot establish clearance at an unsampled closer edge. Lost orientation also prevents reliable localisation of an involved margin.
4.When does breast HER2 immunohistochemistry require reflex ISH?
Breast HER2 immunohistochemistry scored 2+ is equivocal and requires additional assessment, usually reflex in situ hybridisation on the same specimen or testing another suitable specimen. The equivocal category includes weak-to-moderate complete membrane staining in more than 10% of invasive tumour cells. It does not establish gene amplification. Distinguish invasive carcinoma from in situ disease during scoring, and integrate unusual ISH patterns with the guideline's accompanying IHC review requirements.
Apply it
An invasive breast carcinoma shows weak-to-moderate complete membrane staining in 40% of invasive cells. Report an equivocal IHC result and arrange reflex ISH rather than assigning amplified or non-amplified status from staining intensity alone.
Common pitfall: Equivocal protein expression is not a positive amplification result. Calling it definitively positive bypasses the additional testing needed to resolve this category correctly.
HER2 Testing in Breast Cancer – 2023 Guideline Update · HER2 Breast Cancer Testing Guideline Update: Summary of Recommendations
5.Why is a blood-only thyroid aspirate non-diagnostic rather than benign?
Cytology must first establish whether diagnostically useful tissue is represented. A thyroid aspirate consisting entirely of blood, without assessable follicular epithelium or colloid, cannot establish that a solid nodule is benign. The College classifies such a sample as Thy1 and requires the reason for non-diagnostic sampling to be stated. Its usual epithelial cellularity criterion for solid lesions is at least six groups of ten well-visualised follicular cells, interpreted with the clinical and ultrasound context. See the [thyroid cytology guidance](https://www.rcpath.org/static/7d693ce4-0091-4621-97f79e2a0d1034d6/a4e0b2ba-17ae-4826-b299282b60fdc890/g089-guidance-on-reporting-of-thyroid-cytology-specimens.pdf).
Apply it
A solid thyroid nodule yields blood alone. Report Thy1 with the sampling limitation and arrange clinically appropriate repeat targeted sampling rather than reporting a benign nodule.
Common pitfall: Absence of malignant cells in a non-representative sample is not evidence of benignity. Cellular adequacy rules also require context, particularly in colloid-rich cystic samples.
6.Why are internal controls essential when interpreting mismatch-repair loss?
Mismatch-repair immunohistochemistry assesses nuclear expression in tumour cells against non-neoplastic internal controls, such as lymphocytes and stromal cells. Apparent tumour loss is interpretable when the internal controls retain appropriate nuclear staining. If tumour and controls both fail, technical failure or tissue-related artefact must be considered. The decision is therefore not simply whether tumour nuclei look negative, but whether the section demonstrates that the assay could detect the protein.
Apply it
A colorectal carcinoma lacks MLH1 staining, but adjacent lymphocytes and stromal cells are also unstained. Treat the result as technically uninterpretable and repeat or investigate the assay before reporting tumour-specific MLH1 loss.
Common pitfall: A negative stain without a working internal control cannot establish protein loss; treating universal absence as tumour deficiency mistakes assay failure for biology.
7.How does paired MLH1 and PMS2 loss guide further investigation?
MLH1 and PMS2 function as a protein pair, and loss of MLH1 commonly destabilises PMS2, producing combined loss. In colorectal carcinoma, this directs assessment towards MLH1 promoter methylation and, within the appropriate algorithm, BRAF V600E testing. BRAF V600E supports a sporadic pathway associated with MLH1 silencing and makes Lynch syndrome less likely. BRAF negativity does not prove Lynch syndrome because some sporadic MLH1-methylated tumours lack that variant. Confirm intact internal controls before interpreting loss.
Apply it
A colorectal tumour loses MLH1/PMS2, retains MSH2/MSH6 and lacks BRAF V600E. Continue MLH1-pathway evaluation, including methylation assessment as appropriate, rather than classifying the tumour as inherited solely from BRAF negativity.
Common pitfall: The staining pattern identifies an affected pathway, not a germline diagnosis. Neither paired loss nor BRAF negativity independently establishes Lynch syndrome.
8.How should an intraoperative frozen-section answer match the surgical decision?
Clarify the decision the surgeon needs to make and assess whether the submitted tissue can answer it. Presence of lesional tissue, margin involvement and precise tumour classification are different questions. If freezing or sampling prevents reliable assessment of invasion, communicate that specific limitation and preserve tissue for permanent sections; an indeterminate specimen cannot establish a negative margin. Limited sampling and deferred definitive diagnosis are described in this [laboratory frozen-section guide](https://northernlabstestguide.health.nz/test/frozen-section-intraoperative-consultation-fresh-tissue/).
Apply it
A margin specimen is extensively crushed and cannot be assessed for tumour. Explain that clearance cannot be determined from this material, identify the damaged margin and discuss whether an additional representative sample can answer the operative question.
Common pitfall: An unqualified negative answer can drive irreversible surgery despite inadequate evidence. Deferral should identify the unresolved feature and the tissue or processing needed to resolve it.
9.How should autopsy findings support a defensible cause-of-death conclusion?
Integrate the circumstances, clinical records, external examination, internal findings and indicated ancillary investigations. Distinguish an observed abnormality from a causal explanation: an incidental lesion does not become the cause merely because it is visible. Record relevant negative findings and explain competing interpretations. When poisoning is plausible, arrange appropriate toxicology sampling and preservation before material is lost. The College's [autopsy standards](https://www.rcpath.org/asset/1B02CFB9-000A-4B2F-B6B80256B719A5EE/) require justified conclusions and appropriate retention for further investigation.
Apply it
An unexpected death has no convincing anatomical explanation and the history raises possible drug exposure. Preserve and submit appropriately labelled toxicology specimens under the relevant authority, and keep the causal conclusion qualified pending those results.
Common pitfall: A grossly unremarkable examination does not establish a natural death or exclude poisoning. Conversely, detecting a substance requires interpretation before attributing causation.
10.How is Breslow thickness measured in invasive melanoma?
Breslow thickness measures the vertical depth of invasive melanoma from the top of the epidermal granular layer to the deepest invasive melanoma cell. When the surface is ulcerated, measurement begins at the base of the ulcer. The measurement is perpendicular to the skin surface and excludes the thickness of an overlying crust. Accurate orientation matters because an oblique section can distort depth. State measurement limitations when the available tissue prevents a reliable assessment.
Apply it
An ulcerated melanoma has a thick surface crust and an invasive front beneath the ulcer bed. Measure from the ulcer base to the deepest invasive cell, excluding the crust from the recorded Breslow thickness.
Common pitfall: Measuring from the top of a crust exaggerates thickness, while measuring from a residual epidermal landmark across an ulcer can use the wrong starting point.
11.What can a deeply transected melanoma biopsy establish about thickness?
When invasive melanoma reaches the deep biopsy edge, the deepest tumour may remain in the patient. The observed Breslow measurement therefore establishes a minimum thickness, not necessarily the final maximum thickness. Report it with an appropriate qualification, such as at least the measured value, and explain the deep-margin limitation. Additional tissue can reveal greater depth. Avoid assigning an artificially precise final thickness or definitive depth-dependent category from an incomplete invasive front.
Apply it
A shave biopsy contains invasive melanoma extending to the deep edge at 1.3 mm. Communicate a thickness of at least 1.3 mm and explain that the final depth may increase when additional tissue is examined.
Common pitfall: Reporting the measured minimum as the final maximum can understate tumour extent; a numerically precise measurement does not remove uncertainty caused by tissue transection.
12.Which histological findings establish melanoma-associated ulceration?
Ulceration requires full-thickness loss of the epidermis over melanoma, including its surface and basement membrane, accompanied by a reactive response. Supporting findings include fibrin and neutrophils at the defect and thinning, effacement or reactive hyperplasia of the surrounding epidermis. Review the defect with adjacent epidermis, additional levels and procedure history. Epidermal loss caused by prior biopsy or trauma must be distinguished from tumour-associated ulceration; a processing-related separation without an appropriate tissue response is insufficient.
Apply it
A surface defect shows complete epidermal loss, fibrin, neutrophils and reactive adjacent epidermis. Check for a prior biopsy or traumatic explanation before assigning tumour-associated ulceration. A detached epidermal fragment without reactive findings instead raises artefact.
Common pitfall: Neither a surface gap alone nor inflammation alone establishes tumour-associated ulceration. If the available specimen and history cannot distinguish biological ulceration from procedural damage, report the uncertainty.
Haematologynot stated
13.Which pathways do PT and aPTT patterns help investigate?
PT and aPTT are screening tests that narrow the investigation of coagulation abnormalities. An isolated prolonged PT suggests an extrinsic-pathway problem, including factor VII deficiency or early vitamin K-related effects. An isolated prolonged aPTT suggests an intrinsic-pathway factor deficiency, an inhibitor or an anticoagulant effect. Prolongation of both raises common-pathway or multiple-factor abnormalities. Interpret these patterns with medication exposure, sample quality, platelet count and clinical bleeding rather than treating either test as a diagnosis.
Apply it
A patient without anticoagulant exposure has a persistently prolonged PT and normal aPTT. After checking specimen integrity, prioritise an extrinsic-pathway investigation rather than beginning with an isolated factor VIII deficiency explanation.
Common pitfall: Normal screening results do not exclude every bleeding disorder, and an abnormal result does not automatically predict bleeding without identifying its mechanism and clinical context.
14.How does a mixing study distinguish factor deficiency from inhibition?
A mixing study combines patient plasma with normal plasma to investigate a prolonged clotting time. Correction supports a factor deficiency because normal plasma supplies missing activity. Failure to correct suggests an inhibitor or interfering anticoagulant. Some inhibitors are time dependent, so immediate and incubated results can differ. Interpret correction using the laboratory's validated criteria and exclude relevant drug interference before using the pattern to select factor assays or inhibitor investigations.
Apply it
An isolated prolonged aPTT corrects immediately after mixing but becomes prolonged after incubation. Recognise a possible time-dependent inhibitor and pursue appropriate inhibitor and factor investigations instead of concluding that correction excluded inhibition.
Common pitfall: Immediate correction alone cannot exclude every inhibitor. Anticoagulant interference and incubation-dependent effects can make a simple corrected-versus-uncorrected interpretation misleading without appropriate further investigation.
15.Why can a markedly prolonged aPTT occur without clinical bleeding?
The aPTT measures reactions under laboratory conditions, so its prolongation does not uniformly indicate defective haemostasis in vivo. Contact-factor deficiencies, including factor XII deficiency, can markedly prolong aPTT without causing the expected bleeding phenotype. Lupus anticoagulants may also prolong phospholipid-dependent tests without indicating a bleeding disorder. Distinguish these possibilities from factor VIII, IX or XI deficiencies by combining bleeding history, mixing studies, medication review and targeted assays.
Apply it
An asymptomatic adult with previous uncomplicated surgery has a very prolonged aPTT and normal PT. Investigate contact-factor deficiency or an inhibitor pattern rather than assuming severe haemophilia solely from the clotting-time magnitude.
Common pitfall: Using the number of seconds of aPTT prolongation as a direct measure of bleeding severity ignores disorders that alter the assay without impairing clinical haemostasis.
16.Why is abnormal promyelocyte morphology with coagulopathy an emergency?
Abnormal promyelocytes with thrombocytopenia, bleeding and low fibrinogen suggest acute promyelocytic leukaemia (APL), which can cause fatal intracranial or pulmonary haemorrhage through consumptive coagulation and excessive fibrinolysis. Suspected APL requires immediate hospital admission and haematology management: start all-trans retinoic acid (ATRA) on clinical and blood-film suspicion, before PML::RARA confirmation. The fusion protein imposes a differentiation block; ATRA promotes maturation of the abnormal promyelocytes. Simultaneously begin correction of coagulopathy with appropriate platelet, fibrinogen replacement and plasma support while rapid molecular confirmation proceeds. Monitor platelet counts, fibrinogen and coagulation tests at least daily, and more frequently when required. These immediate actions are explicitly recommended by the [European LeukemiaNet](https://www.leukemia-net.org/sites/leukemia-net/content/e58/e480/e7392/e7396/e11507/SanzMAetal2019_Blood.Managementofacutepromyelocyticleukemia-updatedrecommendationsfromanexpertpaneloftheEuropeanLeukemiaNet.pdf).
Apply it
A bleeding patient has heavily granular abnormal promyelocytes containing bundles of Auer rods, platelets of 18 × 10^9/L and fibrinogen of 0.7 g/L. Treat this as suspected APL immediately: initiate ATRA under hospital haematology care, provide haemostatic support and request rapid PML::RARA testing. Rapid FISH can assist diagnosis, with RT-PCR performed in parallel to identify the fusion transcript for subsequent molecular monitoring.
Common pitfall: Waiting for molecular confirmation before starting ATRA risks preventable early death. Conversely, ATRA does not replace immediate correction and repeated assessment of coagulopathy. Conventional cytogenetics can miss cryptic PML::RARA rearrangements. If genetic investigation does not support APL, discontinue empiric ATRA and revise management. Avoid unnecessary invasive procedures while the coagulopathy is active.
Haematology examination regulations 2026 · Prolonged Clotting Time Evaluation · Acute Myeloid Leukemia Treatment (PDQ®) - NCI · SanzMAetal2019_Blood.Managementofacutepromyelocyticleukemia-updatedrecommendationsfromanexpertpaneloftheEuropeanLeukemiaNet.pdf
17.Which findings favour beta-thalassaemia trait in microcytosis?
Beta-thalassaemia trait commonly produces microcytosis disproportionate to the degree of anaemia, with a relatively preserved or increased red-cell count and raised HbA2. Iron studies help distinguish concurrent or alternative iron deficiency. Severe iron deficiency can lower HbA2 and complicate interpretation, while recent transfusion can alter haemoglobin fractions. Use the full blood count, iron status and haemoglobin analysis together rather than diagnosing the trait from a low mean cell volume alone.
Apply it
An adult has MCV 65 fL, mild anaemia, a relatively high red-cell count and normal ferritin. Request haemoglobin analysis and assess HbA2 rather than treating the microcytosis as proven iron deficiency.
Common pitfall: Microcytosis is a shared phenotype, not a diagnosis. Giving repeated iron solely because MCV is low can miss thalassaemia when iron stores are adequate.
18.When can normal haemoglobin analysis still support alpha-thalassaemia testing?
Alpha-thalassaemia trait may cause persistent microcytosis despite normal routine adult haemoglobin fractions. A normal electrophoretic or chromatographic pattern therefore does not exclude it. When the blood count, iron studies and clinical context remain suggestive, alpha-globin genetic testing can clarify the diagnosis. Deletion analysis is particularly relevant because many alpha-thalassaemia variants involve gene deletions; sequencing or broader analysis may be needed when initial testing does not resolve a convincing phenotype.
Apply it
A person with persistent microcytosis has adequate iron stores and no raised HbA2. Consider alpha-globin deletion analysis when the clinical and family context support alpha-thalassaemia, despite an unremarkable routine haemoglobin separation result.
Common pitfall: Assuming that normal haemoglobin electrophoresis excludes every thalassaemia misses alpha-thalassaemia trait, whose adult haemoglobin fractions may be unremarkable despite reduced alpha-globin production and microcytosis.
19.How do several laboratory findings establish a haemolysis pattern?
Haemolysis is supported by a coordinated pattern of increased reticulocytes, increased lactate dehydrogenase and unconjugated bilirubin, and reduced haptoglobin. Each marker has limitations: reticulocytosis may be blunted by marrow dysfunction, LDH is nonspecific, and haptoglobin is influenced by other conditions. Examine the blood film and clinical context to identify mechanism. A coherent pattern is stronger evidence than any isolated abnormality, especially when distinguishing red-cell destruction from impaired production.
Apply it
A patient develops anaemia with increased reticulocytes, indirect hyperbilirubinaemia, high LDH and low haptoglobin. Establish a haemolysis pattern, then use the film and antiglobulin testing to investigate its cause rather than stopping at the raised LDH.
Common pitfall: An isolated LDH rise does not establish haemolysis. Conversely, absent reticulocytosis cannot exclude destruction when marrow response is impaired or the episode is early.
20.What does a direct antiglobulin test add to haemolysis investigation?
The direct antiglobulin test detects immunoglobulin or complement bound to the patient's red cells. In established haemolysis, a positive result supports an immune mechanism, interpreted with clinical history and further serological findings. It does not measure the rate of destruction, and positivity can occur without active haemolysis. A negative routine result does not exclude every immune haemolytic process. First establish whether red-cell destruction is occurring, then interpret the test mechanistically.
Apply it
Two patients have positive direct antiglobulin tests, but only one has falling haemoglobin, reticulocytosis and biochemical evidence of destruction. Explain why active immune haemolysis requires the clinical and haemolysis findings as well as red-cell coating.
Common pitfall: Treating a positive direct antiglobulin test as synonymous with haemolytic anaemia ignores clinically silent red-cell coating and can lead to an unsupported diagnosis or treatment.
21.Which findings should trigger consideration of thrombotic microangiopathy?
Thrombotic microangiopathy is suggested by microangiopathic haemolytic anaemia, thrombocytopenia and organ injury. Schistocytes support mechanical red-cell fragmentation, while haemolysis markers establish destruction. The pattern requires urgent evaluation because causes include thrombotic thrombocytopenic purpura and haemolytic uraemic syndromes. It is unnecessary to wait for every historically described manifestation before considering TTP. Use clinical context and ADAMTS13 testing to distinguish mechanisms while urgent specialist assessment proceeds.
Apply it
A patient has thrombocytopenia, schistocytes, high LDH and new neurological symptoms. Recognise a thrombotic microangiopathy pattern and initiate urgent specialist evaluation instead of waiting for fever and renal failure to complete a historical pentad.
Common pitfall: Requiring the full historical TTP pentad delays recognition. Schistocytes also occur in other disorders, so fragmentation alone does not establish a specific thrombotic microangiopathy.
Thrombotic Microangiopathies – Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome
22.How does severe ADAMTS13 deficiency distinguish TTP?
ADAMTS13 cleaves large von Willebrand factor multimers. Severe deficiency permits platelet-rich microvascular thrombi and supports TTP in a compatible thrombotic microangiopathy. Activity below 10% is the important diagnostic threshold. Additional inhibitor or antibody testing investigates an acquired immune mechanism. Collect a pretreatment specimen whenever feasible because plasma treatment can supply ADAMTS13 and alter inhibitor measurements, but do not delay urgent treatment. Moderate activity reductions are less specific and occur in other illnesses.
Apply it
A patient with thrombocytopenia and microangiopathic haemolysis has pretreatment ADAMTS13 activity of 4%. Use this severe deficiency to support TTP and investigate an immune cause rather than interpreting the value as a nonspecific minor reduction.
Common pitfall: Calling every reduced ADAMTS13 result TTP ignores the severity threshold. A post-plasma result may also fail to represent the patient's untreated activity.
Thrombotic Microangiopathies – Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome
23.How do monoclonal-protein investigations distinguish MGUS, smouldering myeloma and active myeloma?
A monoclonal protein alone does not diagnose myeloma. Non-IgM monoclonal gammopathy of undetermined significance (MGUS) requires serum monoclonal protein below 30 g/L, fewer than 10% clonal marrow plasma cells and no attributable CRAB injury or amyloidosis. Smouldering myeloma requires serum IgG/IgA monoclonal protein at least 30 g/L or urinary monoclonal protein at least 500 mg/24 hours and/or 10% to less than 60% clonal marrow plasma cells, without myeloma-defining events or amyloidosis. Active myeloma requires at least 10% clonal marrow plasma cells or a biopsy-proven bony or extramedullary plasmacytoma, plus at least one myeloma-defining event. CRAB abnormalities must be attributable to the plasma-cell disorder and meet defined criteria: calcium more than 0.25 mmol/L above the upper reference limit or above 2.75 mmol/L; creatinine clearance below 40 mL/min or serum creatinine above 177 micromol/L; haemoglobin more than 20 g/L below the lower reference limit or below 100 g/L; or one or more osteolytic bone lesions on radiography, CT or PET/CT. CT-demonstrated osteolytic destruction must measure at least 5 mm. When marrow contains fewer than 10% clonal plasma cells, more than one bone lesion is required. The SLiM biomarkers also define active myeloma: at least 60% clonal marrow plasma cells; an involved/uninvolved serum free-light-chain ratio at least 100 with involved light chain at least 100 mg/L; or more than one MRI focal lesion, each at least 5 mm.
Apply it
An asymptomatic adult with 65% clonal marrow plasma cells meets active myeloma criteria through the marrow SLiM biomarker despite normal calcium, haemoglobin and renal function and absent lytic lesions. In comparison, 15% clonal marrow plasma cells without any myeloma-defining event or amyloidosis supports smouldering myeloma. Mild abnormalities require numerical assessment: haemoglobin 115 g/L with a lower reference limit of 130 g/L is only 15 g/L below that limit and remains above 100 g/L, so it does not meet the anaemia criterion even if attributable. Evaluate serum electrophoresis and immunofixation, serum free light chains, appropriate urine studies, marrow, blood counts, calcium, renal function and imaging together.
Common pitfall: Absence of CRAB injury does not establish MGUS or smouldering myeloma until all three SLiM biomarkers have been assessed. A free-light-chain ratio of 120 with involved light chain only 80 mg/L fails the biomarker's two-part requirement. Organ abnormalities must satisfy both the relevant threshold and attribution requirement. PET uptake alone does not establish osteolytic bone disease; underlying destruction must be demonstrated on CT. Osteoporosis or vertebral compression fractures without lytic lesions are insufficient to meet the CRAB bone criterion.
Haematology examination regulations 2026 · IMWG Criteria for the Diagnosis of MM | Inl Myeloma Fn · Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®) - NCI
24.What is the immediate response to a severe suspected transfusion reaction?
Stop the transfusion immediately when a severe reaction is suspected, assess airway, breathing and circulation, and obtain urgent clinical assistance. Maintain intravenous access using an appropriate separate line according to the reaction protocol, check patient and component identification, and notify the transfusion service. Preserve the component and administration set for investigation as directed. Fever, hypotension or respiratory compromise can represent several dangerous mechanisms; identifying the exact mechanism follows the immediate interruption and stabilisation.
Apply it
During red-cell transfusion, a patient develops rigors, hypotension and breathlessness. Stop the component, summon urgent assistance and assess the patient while identity checks and transfusion-service communication proceed, rather than continuing at a slower rate.
Common pitfall: Labelling the event a simple febrile reaction before excluding serious causes can prolong exposure to an incompatible or contaminated component and delay essential resuscitation measures.
Clinical Biochemistrynot stated
25.How does PTH separate major mechanisms of hypercalcaemia?
PTH should normally fall when calcium is high. Hypercalcaemia with an elevated or inappropriately normal PTH therefore suggests a PTH-dependent process, whereas suppressed PTH directs investigation towards PTH-independent causes. A result inside the population reference interval can still be physiologically abnormal when calcium is elevated. Confirm the calcium abnormality and interpret renal function, medications and other biochemical findings before assigning a specific cause such as primary hyperparathyroidism.
Apply it
Repeated testing confirms hypercalcaemia, but PTH lies near the middle of its reference interval. Recognise that PTH is inadequately suppressed and investigate a PTH-dependent mechanism rather than dismissing the hormone result as normal.
Common pitfall: Reading each value against its reference interval independently misses physiological feedback. In hypercalcaemia, a reference-range PTH can be inappropriate rather than reassuring evidence against disease.
26.How should a chromatographic output be converted into a reportable concentration?
Interpret peak identity and integration before applying the validated calibration model and any dilution factor. In an illustrative method with a linear calibration through zero, an analyte-to-internal-standard area ratio of 0.50 corresponds to 20 micromol/L. A sample ratio of 1.00 therefore represents 40 micromol/L in the analysed preparation. If the original specimen was diluted twofold, its concentration is 80 micromol/L. This calculation assumes acceptable separation, controls and calibration over the relevant range.
Apply it
The sample and calibrator have acceptable peak separation and internal-standard recovery. Calculate 1.00/0.50 × 20 × 2 = 80 micromol/L, then check that the diluted preparation lies within the validated measuring range.
Common pitfall: A matching retention time alone does not establish unambiguous identity. Ignoring coelution, invalid calibration or the dilution factor can produce a precise but incorrect numerical report.
27.Which vitamin D measurement assesses usual nutritional status?
Serum 25-hydroxyvitamin D is generally the appropriate measure of vitamin D stores. The active metabolite, 1,25-dihydroxyvitamin D, is tightly regulated by PTH, calcium and renal processes and can remain normal or rise despite depleted stores. Its measurement answers selected mechanistic questions, including some PTH-independent hypercalcaemic states, rather than routine nutritional assessment. Choose the analyte according to the clinical question instead of assuming that the biologically active form is always the best screening test.
Apply it
An adult with bone pain and low calcium has raised PTH, preserved renal function and markedly reduced 25-hydroxyvitamin D. Interpret the PTH rise as a compensatory response compatible with vitamin D depletion; a normal active-metabolite result would not exclude depleted stores.
Common pitfall: A normal active-metabolite result does not exclude depleted vitamin D stores; regulated hormone production can preserve that concentration while the storage marker is reduced.
28.How can an inherited calcium phenotype resemble primary hyperparathyroidism?
Familial hypocalciuric hypercalcaemia (FHH) and primary hyperparathyroidism can both produce hypercalcaemia with non-suppressed PTH. FHH results from impaired calcium-sensing signalling, usually through an autosomal dominant loss-of-function variant in CASR, GNA11 or AP2S1. The parathyroid calcium threshold for suppressing PTH rises, while reduced renal calcium excretion contributes to relative hypocalciuria. Lifelong, non-progressive hypercalcaemia and affected relatives favour FHH. Calculate the calcium/creatinine clearance ratio (CCCR) using concurrent serum and 24-hour urine measurements: CCCR = (urine calcium × serum creatinine) / (serum calcium × urine creatinine). Use matching units for each analyte across serum and urine. A ratio below 0.01 supports consideration of FHH, but substantial overlap prevents definitive discrimination: this threshold captures approximately 65% of FHH type 1 cases, while approximately 18% of surgically confirmed primary hyperparathyroidism cases also fall below it.
Apply it
In an illustrative case, a young adult and a parent have longstanding mild hypercalcaemia. Concurrent serum calcium is 2.80 mmol/L and serum creatinine is 0.080 mmol/L; calcium and creatinine concentrations in the 24-hour urine collection are 1.0 mmol/L and 5.0 mmol/L respectively. CCCR = (1.0 × 0.080) / (2.80 × 5.0) = approximately 0.0057. This supports investigating FHH alongside the family history, but does not confirm it. Assess renal function, vitamin D status, medication use and collection completeness. Genetic assessment is recommended for suspected FHH, particularly with lifelong hypercalcaemia and affected relatives, before committing to parathyroid surgery.
Common pitfall: Renal impairment and vitamin D insufficiency limit CCCR interpretation; the ratio has not been validated for diagnosing FHH in these settings. Thiazides can lower urinary calcium and CCCR by enhancing renal calcium reabsorption, creating an FHH-like result. The ESE consensus recommends collecting urine after withholding thiazides for at least one week when clinically appropriate. Correct vitamin D insufficiency before interpreting PTH. A pathogenic or likely pathogenic variant can confirm FHH, whereas a variant of uncertain significance requires further evaluation, including family segregation. Negative genetic testing does not exclude FHH; historical calcium results and family testing remain informative.
Hypercalcemia and Hypocalcemia – Vitamin D Testing · European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021) - PMC · phpt_concise_summary_final_020322.pdf
29.Why can central hypothyroidism be missed by TSH-only testing?
Central hypothyroidism results from inadequate hypothalamic or pituitary stimulation of the thyroid. Free T4 is low, but TSH may be low, normal or otherwise inappropriately non-elevated for the degree of hormone deficiency. TSH-only screening can therefore miss disease when pituitary dysfunction is plausible. Measure and interpret free T4 in that setting, while considering illness and assay interference. A normal TSH does not demonstrate an intact thyroid axis under all circumstances.
Apply it
A patient with a pituitary lesion has symptoms compatible with hypothyroidism, low free T4 and a reference-range TSH. Recognise the inappropriate pituitary response rather than using the normal TSH to exclude thyroid-axis dysfunction.
Common pitfall: The primary-thyroid feedback rule cannot be transferred unchanged to pituitary disease. Low free T4 with non-elevated TSH requires contextual assessment rather than automatic reassurance.
30.How can biotin mimic biochemical hyperthyroidism?
Biotin can interfere with assays that use biotin-streptavidin binding, with the direction depending on assay design. In susceptible sandwich assays it may produce falsely low results, while susceptible competitive assays may produce falsely high results. A combination of falsely low TSH and falsely high free thyroid hormones can resemble hyperthyroidism. Ask about supplements and discuss the platform with the laboratory when results conflict with the patient; susceptibility and appropriate reassessment depend on the assay and exposure.
Apply it
A clinically euthyroid patient taking a high-dose hair supplement has low TSH and high free T4 on a susceptible platform. Investigate biotin interference and obtain an appropriately planned reassessment before accepting biochemical thyrotoxicosis.
Common pitfall: Biotin does not affect every method identically. Assuming a universal direction or universal interruption interval ignores platform design, supplement exposure and individual clearance circumstances.
Analytical Considerations in the Evaluation of Thyroid Function · Meeting the Biotin Challenge | myadlm.org
31.What distinguishes analytical imprecision from bias?
Imprecision is the spread of repeated measurements, while bias is a systematic difference from an appropriate target or reference value. A method can be highly precise yet consistently wrong. Repeated control measurements help characterise random variation; comparison with assigned or reference values helps identify systematic error. Corrective action should address the demonstrated mechanism. Recalibration may correct a systematic offset, whereas unstable pipetting or inconsistent operating conditions may primarily increase imprecision.
Apply it
A control with a target of 100 repeatedly measures near 112 with very little scatter. Identify substantial positive bias despite good precision, and investigate calibration or systematic method effects rather than describing the assay as accurate.
Common pitfall: Tightly clustered results establish repeatability, not trueness. A narrow distribution around the wrong value can consistently misclassify patients despite apparently excellent analytical precision performance.
Laboratory Quality Management System Training Toolkit: Quantitative QC, Module 7
32.How is coefficient of variation calculated and compared?
Coefficient of variation expresses standard deviation relative to the mean: CV equals standard deviation divided by mean, multiplied by 100%. It provides a percentage measure of imprecision and can help compare performance at different concentrations. For a mean of 120 and standard deviation of 3, CV is 2.5%. Comparisons still require attention to concentration and intended use because many assays show different relative imprecision near their lower measuring limits.
Apply it
Two controls have mean/SD pairs of 80/2 and 200/4. Calculate CVs of 2.5% and 2.0% respectively, recognising that the second has lower relative imprecision despite its larger absolute standard deviation.
Common pitfall: Comparing standard deviations alone ignores scale. CV also becomes unstable near a mean of zero and should not be used without considering concentration-dependent assay behaviour.
Laboratory Quality Management System Training Toolkit: Quantitative QC, Module 7
33.How do quality-control shifts and trends suggest different problems?
A shift is a sustained change in the control mean, often appearing after a discrete event such as recalibration or a reagent change. A trend is a progressive movement over successive runs, suggesting gradual change such as deterioration or instrument drift. Review the sequence and relevant maintenance records rather than evaluating each control result in isolation. Values can reveal an emerging systematic problem before any single result exceeds a simple acceptance boundary.
Apply it
After a reagent lot change, successive control values cluster above their former mean without progressive further increase. Recognise a shift and investigate the lot transition rather than describing the pattern as random scatter.
Common pitfall: Accepting every result merely because it remains inside a broad limit can miss a sustained systematic change that is evident from the control sequence.
Laboratory Quality Management System Training Toolkit: Quantitative QC, Module 7
34.Why does strong correlation fail to establish agreement between methods?
Correlation describes association, so it can remain excellent despite systematic disagreement. Consider an illustrative comparison of 40 independent patient specimens in which the new method consistently returns 1.10 times the comparator result, with negligible scatter. The relationship can have correlation close to 1 while retaining 10% proportional bias. Compare paired differences against prespecified allowable error across the clinical range. Assess replication, specimen selection, uncertainty and clinically important concentrations before accepting the study's conclusion.
Apply it
A study reports correlation of 0.999 and a fitted relationship of new result = 1.10 × comparator result. At comparator values of 100 and 300, expected differences are +10 and +30. This fails an illustrative prespecified ±5% agreement requirement despite high correlation.
Common pitfall: Repeated measurements of a few specimens do not provide the same evidence as independent patient samples. A significant correlation or small P value does not establish clinical interchangeability.
Source · Laboratory Quality Management System Training Toolkit: Quantitative QC, Module 7
35.How are diagnostic sensitivity and specificity calculated?
Sensitivity is the proportion of people with the target condition who test positive: true positives divided by true positives plus false negatives. Specificity is the proportion without the condition who test negative: true negatives divided by true negatives plus false positives. Both require a defensible reference standard and a clearly defined study population. They answer different questions from predictive values. Report the denominators explicitly so that missed disease and false-positive classification are not confused.
Apply it
Among 100 reference-positive patients, a test detects 90; among 200 reference-negative patients, it correctly excludes 180. Calculate sensitivity and specificity as 90% each, keeping the diseased and non-diseased denominators separate during interpretation.
Common pitfall: Dividing true positives by all positive results calculates positive predictive value, not sensitivity. Incorrect denominators can make an otherwise accurate numerical calculation answer the wrong question.
Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
36.Why does disease prevalence change positive predictive value?
Positive predictive value is the proportion of positive results that are true positives. Even with unchanged sensitivity and specificity, testing a lower-prevalence population can produce many false positives relative to true positives because the non-diseased group is much larger. Calculate expected counts using the relevant population rather than quoting sensitivity as the probability that a positive result means disease. Clinical selection and the intended-use setting therefore materially influence interpretation of a positive test.
Apply it
In 10,000 people with 1% prevalence, a 90%-sensitive and 95%-specific test produces 90 true positives and 495 false positives. Calculate positive predictive value as 90/585, approximately 15.4%, rather than 90%.
Common pitfall: High sensitivity does not make every positive result convincing. Predictive value depends on the population and can fall substantially when testing people with low prior probability.
Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
Infectionnot stated
37.What does each component of the hepatitis B triple panel establish?
The hepatitis B triple panel comprises HBsAg, anti-HBs and total anti-HBc. HBsAg indicates current infection when confirmed and appropriately interpreted. Anti-HBs indicates an immune response associated with recovery or vaccination. Total anti-HBc indicates exposure to the virus and is not produced by vaccination alone. Read the combination rather than a single marker because immunity after infection differs from vaccine-associated immunity. Additional markers, timing and clinical information resolve particular acute or uncertain patterns.
Apply it
A screening request asks whether a patient has current infection, previous infection or vaccine-associated immunity. Use all three markers to distinguish those possibilities instead of requesting anti-HBs alone and assuming it answers every question.
Common pitfall: Anti-HBs alone cannot distinguish vaccination from recovery after infection; total anti-HBc supplies the exposure information needed to separate those two common immune patterns reliably.
38.Why does conjugating a bacterial polysaccharide improve vaccine responses in young children?
Pure polysaccharides usually stimulate T-cell-independent B-cell responses and are inconsistently immunogenic in children younger than two years. Linking a polysaccharide to a protein carrier recruits T-cell help and produces more durable protective immunity to the polysaccharide. This explains why a conjugate vaccine and a pure polysaccharide vaccine are not immunologically interchangeable even when they target the same organism. The mechanism is described in the [CDC vaccination principles](https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-1-principles-of-vaccination.html).
Apply it
When comparing pneumococcal vaccine platforms for an infant, explain the protein carrier's role in improving the response rather than assuming that a larger number of polysaccharide antigens necessarily provides the more suitable platform.
Common pitfall: Vaccine selection depends on age, indication and the applicable schedule as well as antigen coverage. Antigen count alone does not describe immune-response quality.
39.How should a reactive HIV antigen/antibody screen with negative antibody differentiation be resolved?
Early HIV infection can produce detectable viral antigen or RNA before a mature antibody response. In the CDC laboratory algorithm, a reactive antigen/antibody screen followed by negative or indeterminate HIV-1/HIV-2 antibody differentiation requires HIV RNA testing to distinguish acute infection from a false-reactive screen. Neither result alone resolves the discordance. A recent exposure with compatible symptoms can also justify RNA testing despite a negative initial screen. See the [CDC HIV diagnostic guidance](https://www.cdc.gov/std/treatment-guidelines/hiv.htm).
Apply it
A patient with a recent exposure and febrile illness has a reactive combination screen but negative differentiation assay. Request the resolving HIV RNA test rather than reporting the antibody result as excluding infection.
Common pitfall: Antibody negativity during the window period is not equivalent to absence of infection. Also avoid treating a reactive screening assay alone as a fully established diagnosis.
40.Why is isolated total anti-HBc an unresolved hepatitis B pattern?
Isolated total anti-HBc means HBsAg and anti-HBs are negative while total anti-HBc is positive. Possible explanations include remote resolved infection with waned anti-HBs, a false-positive result, occult infection or a window-period pattern. These possibilities have different implications, especially before immunosuppression. Review exposure risk, prior results and immune status, and select additional assessment accordingly. The pattern does not justify automatically labelling the person either susceptible or currently infected.
Apply it
Before immunosuppressive therapy, screening shows isolated total anti-HBc. Flag the unresolved exposure pattern and arrange context-appropriate evaluation, potentially including HBV DNA assessment, rather than recording the patient as simply vaccine-naive and closing the investigation.
Common pitfall: A negative HBsAg does not resolve every isolated-core pattern. Ignoring previous infection or occult infection can miss clinically important risk when immunosuppression is planned later.
41.What does a positive IGRA establish about tuberculosis?
An interferon-gamma release assay detects an immune response to tuberculosis-associated antigens and supports infection with Mycobacterium tuberculosis. It does not determine whether infection is latent or active. A positive result therefore requires clinical evaluation for disease, including symptom assessment, chest imaging and microbiological investigation when indicated. The distinction matters because latent-infection management differs from treatment of active tuberculosis. Immune sensitisation alone cannot establish the anatomical site, infectiousness or current disease burden.
Apply it
An asymptomatic person has a positive IGRA during screening. Arrange evaluation to exclude active tuberculosis before classifying latent infection, rather than treating the immune-response result as proof of contagious pulmonary disease in that person.
Common pitfall: A positive immune test is not a microbiological demonstration of active disease. It cannot independently determine infectiousness or distinguish latent infection from symptomatic tuberculosis.
42.When should suspected active tuberculosis be investigated beyond an IGRA?
Symptoms, exposure history and imaging can create suspicion of active tuberculosis regardless of an IGRA result. Evaluation of possible pulmonary disease includes appropriate respiratory specimens for bacteriological testing, with molecular and culture-based investigations selected through the diagnostic pathway. IGRA is an infection test rather than an adequate stand-alone disease exclusion test. Do not let screening terminology displace clinical assessment when weight loss, persistent respiratory symptoms or compatible radiology indicate possible active disease.
Apply it
A patient with persistent cough, weight loss and suspicious chest imaging has a negative IGRA. Continue investigation for active tuberculosis with appropriate respiratory testing rather than stopping because the immune screening test is negative.
Common pitfall: Using an IGRA as the sole gatekeeper for respiratory microbiology can miss active tuberculosis. Disease suspicion should determine the need for further investigation and appropriate precautions.
43.Why does malaria remain urgent in a febrile traveller who took prophylaxis?
Prophylaxis reduces risk but does not exclude malaria. A febrile person returning from a malaria-endemic area needs urgent assessment with thick and thin blood films. Thick films improve parasite detection; thin films help identify species and quantify parasitaemia. If the first films are negative but suspicion remains, repeat films at 12–24-hour intervals for three sets. A rapid diagnostic test can assist but does not replace microscopy. See the [CDC malaria diagnostic guidance](https://www.cdc.gov/malaria/hcp/clinical-guidance/evaluation-and-diagnosis.html).
Apply it
A traveller develops fever after returning from an endemic area despite reported prophylaxis. Arrange urgent films and assess severity immediately; one negative film should not end evaluation when the exposure and illness remain convincing.
Common pitfall: Assuming prophylaxis guarantees protection or waiting for periodic fever can delay recognition. Record itinerary and travel dates rather than relying on a broad regional label.
44.Why can a positive C. difficile molecular test indicate colonisation?
A molecular assay detects genetic material associated with toxigenic C. difficile, but detection does not establish that toxin-mediated disease explains the patient's symptoms. Colonised people can test positive. Interpret results in patients with compatible diarrhoea, considering alternative causes and the local testing algorithm. Highly sensitive organism detection can therefore have limited clinical specificity when testing is applied indiscriminately. The decisive issue is the relationship between the laboratory finding and a compatible clinical syndrome.
Apply it
A patient receiving laxatives has loose stools and a positive C. difficile NAAT. Review the diarrhoea history, alternative causes and any toxin-algorithm results before assuming that organism detection establishes symptomatic toxin-mediated infection in this case.
Common pitfall: Molecular positivity does not measure current toxin activity or prove causation. Testing patients without a compatible syndrome increases the risk of diagnosing colonisation as disease.
45.Which infection-prevention actions should accompany suspected C. difficile diarrhoea?
Initiate appropriate contact precautions while clinically suspected C. difficile diarrhoea is evaluated. Use a single room with a dedicated toilet where available, dedicated equipment and appropriate hand hygiene. Clean the environment and shared equipment with an effective C. difficile sporicidal agent. Precautions address transmission risk and should not wait for complete diagnostic resolution. The [CDC infection-prevention guidance](https://www.cdc.gov/c-diff/hcp/clinical-guidance/index.html) combines isolation, cleaning, testing stewardship and antimicrobial stewardship.
Apply it
A patient develops new clinically significant diarrhoea on a ward. Begin precautions and dedicated equipment while reviewing laxatives and testing indications; communicate the concern during transfers rather than waiting for a final toxin result.
Common pitfall: A test of cure is not a reliable basis for ending precautions because detection can persist. Clinical resolution and the applicable infection-control policy guide subsequent decisions.
Infection · Clinical Testing and Diagnosis for C. diff Infection
46.How can specimen handling influence C. difficile toxin detection?
C. difficile toxin can degrade in stool when specimens are not tested or stored appropriately. A negative toxin result may therefore reflect analytical sensitivity or preanalytical deterioration as well as true absence. Prompt processing and correct storage support valid interpretation. Discordant results should be assessed through the laboratory's validated algorithm and clinical context, rather than assuming either that every toxin-negative result excludes disease or that every molecular-positive result proves it.
Apply it
A stool specimen remains unrefrigerated for a prolonged interval before a toxin assay is performed. Consider toxin instability when interpreting a negative result, and discuss the handling deviation with the laboratory alongside the clinical assessment.
Common pitfall: Repeating an unstable-analyte assay on the same mishandled specimen cannot restore lost toxin. A technically completed assay may still have reduced interpretability because of preanalytical deterioration.
47.What does EUCAST susceptible, increased exposure mean?
EUCAST category I means susceptible, increased exposure: therapeutic success is likely when exposure is increased through the regimen or concentration at the infection site. It is a susceptibility category with an exposure condition. Interpretation requires the relevant organism-drug breakpoint and clinical setting. An epidemiological cut-off instead separates wild-type from non-wild-type susceptibility distributions; exceeding it does not automatically establish clinical resistance. Clinical breakpoints incorporate exposure and additional evidence about likely treatment success.
Apply it
An isolate is reported as I under EUCAST. Review the required exposure and infection site before selecting the agent. If only an epidemiological cut-off is available, do not substitute that boundary for a clinical susceptibility category.
Common pitfall: Reading I as resistant loses its current EUCAST meaning. Conversely, using ordinary exposure without checking requirements can undermine efficacy; non-wild-type status alone is not a dosing instruction.
48.How should microbiology results change an empirical antimicrobial plan?
Review whether infection remains the correct diagnosis, whether the recovered organism explains the syndrome and whether the initial agent provides effective exposure at the infected site. Incorporate susceptibility, clinical response, allergy, organ function and source control. When the evidence supports it, replace unnecessary broad or duplicate coverage with a suitable targeted regimen and define duration. A positive culture does not automatically require treatment if it represents colonisation. These review principles underpin the [CDC hospital stewardship framework](https://www.cdc.gov/antibiotic-use/hcp/core-elements/hospital.html).
Apply it
A clinically improving patient has a confirmed bacterial source and a susceptible isolate. Review opportunities to narrow therapy and change route when appropriate, rather than continuing every empirical agent merely because improvement began during combination treatment.
Common pitfall: Susceptibility alone does not prove that an organism is causing disease or that a drug reaches the relevant site. Effective treatment may also require drainage or removal of an infected device.
Immunology and Allergynot stated
49.Why does allergen-specific IgE demonstrate sensitisation rather than allergy alone?
Allergen-specific IgE identifies an immune response to an allergen, but clinical allergy requires a compatible relationship between exposure and symptoms. Some sensitised people tolerate the substance without reactions. Interpret the result alongside symptom timing, reproducibility and the exposure history, rather than using positivity as a stand-alone diagnosis. The distinction is particularly important when broad testing identifies unexpected positives that do not correspond to the patient's actual clinical experiences.
Apply it
A patient regularly eats a food without symptoms but has a positive specific-IgE result from a broad panel. Explain that this establishes sensitisation and does not, by itself, establish a clinically relevant food allergy.
Common pitfall: A positive result can tempt unnecessary avoidance when the history shows tolerance. Laboratory sensitisation and reproducible exposure-related disease are different findings that require integration clinically.
50.What can total IgE establish about an allergic disorder?
Total IgE measures the overall circulating IgE concentration rather than the response to a particular allergen. An elevated value can occur in allergic disease but is nonspecific, while a reference-range value does not exclude clinically important allergy. It cannot identify the responsible trigger. Select specific investigations from the history and interpret them in relation to symptoms. Total IgE is therefore contextual information rather than a binary screening answer to every suspected allergic condition.
Apply it
A patient has reproducible symptoms after a particular exposure but total IgE within the reference interval. Continue history-directed assessment instead of excluding allergy solely because the overall circulating IgE concentration is not elevated.
Common pitfall: High total IgE does not identify an allergen, and normal total IgE cannot rule out every allergic disorder. Neither result replaces a specific exposure history.
51.Why should lymphocyte flow-cytometry percentages be converted to absolute counts?
Flow cytometry enumerates lymphocyte subsets, but a normal percentage can conceal depletion when the total lymphocyte count is low. If CD4 cells are 40% of lymphocytes and the absolute lymphocyte count is 0.5 × 10^9/L, the absolute CD4 count is 0.2 × 10^9/L. Interpret against age-appropriate intervals and assess function separately.
Apply it
In recurrent opportunistic infection, calculate the absolute subset counts and investigate cellular immunity; a preserved CD4 percentage does not resolve lymphopenia.
Common pitfall: Cell numbers and percentages do not establish functional competence. Appropriate functional testing may still be needed.
Immunology and allergy examination regulations 2026 · PID-Nov-2015.pdf
52.Which history makes alpha-gal syndrome a plausible diagnosis?
Alpha-gal syndrome is assessed through compatible allergic episodes, relevant exposures and alpha-gal-specific IgE. Delayed reactions after mammalian products, often with a history of tick exposure, provide a useful discriminating pattern. The clinical history determines whether a positive laboratory result is relevant. The diagnosis should integrate the nature and timing of symptoms rather than applying a general expectation that every food-related allergic reaction must occur immediately after eating.
Apply it
A patient reports recurrent nocturnal urticaria several hours after mammalian-meat meals and recalls tick bites. Use the delayed exposure pattern to consider alpha-gal syndrome and request clinically directed assessment rather than dismissing food involvement.
Common pitfall: Expecting all food-associated IgE reactions to begin immediately can miss the delayed alpha-gal pattern. Timing should refine the differential rather than automatically exclude an allergic mechanism.
53.What does immunofixation add to a discrete electrophoretic band?
Serum protein electrophoresis can identify and quantify a discrete component. Immunofixation characterises its immunoglobulin heavy and light chains, such as IgG kappa. Total IgG also includes background polyclonal IgG and should not be equated with the monoclonal component. See the [NCI plasma-cell guidance](https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq).
Apply it
An electrophoretic band measures 12 g/L while total IgG is 20 g/L. Report the band measurement and immunofixation identity separately.
Common pitfall: Band identity does not independently classify the underlying plasma-cell disorder or establish myeloma.
54.Which complement pattern suggests an early classical-pathway defect?
CH50 assesses functional activity across the classical pathway and shared terminal components, whereas AH50 assesses the alternative pathway and shared terminal components. A low or absent CH50 with preserved AH50 directs attention towards an early classical-pathway abnormality. Follow with appropriate component measurements and clinical evaluation. The pattern localises a functional problem; it does not identify a specific inherited defect without further testing or exclude acquired consumption and specimen-related effects.
Apply it
A patient with recurrent infections has repeatedly absent CH50 and normal AH50 in properly handled samples. Prioritise investigation of early classical components instead of assuming that all complement pathways are non-functional or identifying a specific component prematurely.
Common pitfall: CH50 is a functional pathway screen, not a direct measurement of one protein. An abnormal result requires localisation and confirmation before assigning a named inherited deficiency.
Complement Testing – Complement Deficiency and Anticomplement Therapeutic Response Monitoring
55.Which complement pattern directs investigation towards the alternative pathway?
Low or absent AH50 with preserved CH50 suggests an abnormality affecting the alternative pathway rather than an early classical component or a shared terminal component. Follow-up can examine relevant alternative-pathway factors according to the clinical presentation. Interpret functional results with attention to specimen integrity and acquired influences. The distinction depends on comparing both assays: either result alone supplies less localisation than the paired pattern and cannot establish a particular molecular diagnosis.
Apply it
A patient undergoing immunodeficiency investigation has normal CH50 but repeatedly absent AH50. Direct follow-up towards alternative-pathway factors while reviewing sample quality, instead of interpreting the normal classical screen as proof of normal overall complement function.
Common pitfall: A normal CH50 does not test every complement route. Relying on that assay alone can miss an alternative-pathway abnormality that becomes evident through paired functional testing.
Complement Testing – Complement Deficiency and Anticomplement Therapeutic Response Monitoring
56.How should ANA, anti-dsDNA and complement be integrated in suspected systemic autoimmunity?
ANA is sensitive for systemic lupus erythematosus but lacks diagnostic specificity. Anti-dsDNA and anti-Sm are more specific, although less sensitive. In a compatible clinical setting, rising anti-dsDNA with falling C3/C4 supports concern for increased disease activity, particularly renal involvement. Evaluate urine, renal function and symptoms rather than diagnosing or treating a flare from serology alone. Immune-complex consumption can reduce complement function; low CH50 and AH50 can also reflect shared-component deficiency. See the [BSR lupus guideline](https://academic.oup.com/rheumatology/article/57/1/e1/4318863).
Apply it
A patient with lupus develops proteinuria and haematuria alongside rising anti-dsDNA and falling C3/C4. Quantify urinary protein, assess renal function and arrange prompt renal evaluation rather than repeating ANA as the activity test.
Common pitfall: Isolated ANA positivity does not establish lupus. Persistently abnormal serology without clinical activity also does not automatically justify treatment escalation.
Immunology and allergy examination regulations 2026 · Complement Testing – Complement Deficiency and Anticomplement Therapeutic Response Monitoring
57.Which complement mechanism can escape normal CH50 and AH50 screening?
Isolated lectin-pathway dysfunction, including mannose-binding lectin deficiency, can coexist with normal CH50 and AH50 because those assays assess classical and alternative initiation. In recurrent bacterial sinopulmonary infections with otherwise reassuring humoral and complement assessment, lectin-pathway functional testing or mannose-binding lectin measurement may be informative. A low isolated result does not establish the cause of symptoms.
Apply it
Consider lectin-pathway assessment when recurrent infections remain unexplained despite normal CH50, AH50 and humoral testing.
Common pitfall: Interpret a lectin-pathway finding alongside infection severity, other immune defects and alternative explanations; avoid attributing symptoms to it automatically.
PID-Nov-2015.pdf · Complement Testing – Complement Deficiency and Anticomplement Therapeutic Response Monitoring
58.How does IgA deficiency change coeliac serology?
IgA-based coeliac tests can be falsely reassuring when the patient has IgA deficiency. Assess total IgA alongside the relevant IgA serology, and use appropriate IgG-based tests, such as tissue transglutaminase IgG or deamidated gliadin peptide IgG, when IgA is deficient. Interpret results with symptoms and gluten exposure. The underlying principle is that an antibody assay cannot reliably exclude disease when the patient's ability to produce that antibody class is substantially reduced.
Apply it
A patient with malabsorptive symptoms has negative tissue transglutaminase IgA and markedly reduced total IgA. Select appropriate IgG-based coeliac serology instead of treating the negative IgA result as reliable evidence against the diagnosis.
Common pitfall: Ordering only an IgA-specific disease marker can miss coeliac disease in IgA deficiency. A negative result needs an adequate antibody-class background to be reassuring.
59.Why does gluten restriction reduce the sensitivity of coeliac testing?
Coeliac serological activity depends on gluten exposure, so restriction before investigation can lower antibody concentrations and produce falsely reassuring results. Document the diet before interpreting negative serology. Further evaluation may require a specialist-planned approach to exposure and testing, taking symptoms and circumstances into account. The key diagnostic limitation is that a negative test obtained after substantial gluten avoidance does not carry the same exclusion value as testing during adequate exposure.
Apply it
A patient has avoided gluten for months and now has negative coeliac serology despite a suggestive earlier history. Record the dietary restriction and plan further assessment rather than concluding that the negative antibody result definitively excludes disease.
Common pitfall: A symptomatic response to gluten avoidance does not establish coeliac disease, while negative serology after avoidance cannot reliably exclude it. Exposure conditions affect interpretation in both directions.
60.When is HLA testing useful in an uncertain coeliac assessment?
HLA-DQ2 and HLA-DQ8 confer susceptibility to coeliac disease, but their presence does not establish the diagnosis because these types also occur in people without disease. Absence of both makes coeliac disease very unlikely and can help in selected uncertain assessments, including patients already restricting gluten or with discordant findings. HLA testing assesses genetic susceptibility, not current intestinal injury. Integrate it with serology, gluten exposure and other indicated diagnostic assessment.
Apply it
A gluten-restricting patient has inconclusive previous testing. Use HLA-DQ2/DQ8 assessment for its exclusion value, explaining that a positive susceptibility result would leave the diagnosis unresolved rather than confirming active disease.
Common pitfall: Treating HLA-DQ2 or HLA-DQ8 positivity as diagnostic confuses genetic susceptibility with established disease. Their principal value in uncertain cases is qualified exclusion when both are absent.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Separate biological findings from assay limitations: internal staining controls, specimen timing, tissue representation, analytical interference and toxin stability.
- Interpret patterns before naming diseases: paired mismatch-repair loss, PT/aPTT relationships, haemolysis markers, calcium/PTH feedback and complement pathway screens.
- Practise calculations with explicit denominators, including chromatographic dilution factors, absolute lymphocyte counts, coefficient of variation and predictive values.
- Connect laboratory interpretation to decisions: margin sampling, frozen-section limitations, suspected APL, antimicrobial selection and infection precautions.
- Integrate systemic and metabolic cases: inherited hypercalcaemia, vitamin D depletion, monoclonal proteins and autoimmune renal warning signs.
- Use the chosen specialty's official curriculum and examination outline as the full scope, extending these selective examples through practical reporting and clinical case work.
A practical preparation plan
1. Build a specialty interpretation map
For each relevant topic, connect the clinical question to specimen requirements, the measured analyte, the expected pattern and the next investigation. Begin with the worked concepts here, then expand the map using the complete official specialty curriculum.
2. Rehearse paired and discordant results
Compare results that are easily confused: grade versus stage, immediate versus incubated mixing, monoclonal-band measurement versus total immunoglobulin, and CH50 versus AH50. State what each pattern supports and what it cannot establish.
3. Calculate before interpreting
Work through analytical-output, quality-control and diagnostic-accuracy datasets without looking at the explanations. Write the denominator and any dilution factor first, calculate the result and explain its clinical meaning. Assess agreement rather than accepting correlation alone.
4. Turn each case into a practical explanation
Give a brief report or oral explanation containing the decisive evidence, a justified conclusion and a specific limitation. Add the immediate action for time-critical patterns such as suspected APL, TTP, malaria or a severe transfusion reaction.
5. Use errors to choose the next exercise
Complete the 20 independent questions, then classify mistakes as knowledge gaps, incorrect mechanisms, denominator errors or overinterpretation. Revisit the linked concept and answer its flashcard from memory before attempting a different case on the same principle.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Regulations, Guidelines and Policies
- Regulations, Guidelines and Policies Documents
- Fellowship, Diploma and Certificate examinations: regulations and guidelines for 2026
- Histopathology examination regulations 2026
- Haematology examination regulations 2026
- Clinical biochemistry examination regulations 2026
- Clinical Biochemistry
- FRCPath Part 1 and Combined Infection Certificate Examination (CICE) regulations 2026
- Infection
- Immunology and allergy examination regulations 2026
- HER2 Testing in Breast Cancer – 2023 Guideline Update
- HER2 Breast Cancer Testing Guideline Update: Summary of Recommendations
- Colon and Rectum Biomarker Reporting, version 1.3.0.0
- Invasive Melanoma of the Skin: Biopsy, version 1.1.0.0
- Tumor Grade
- Cancer Staging
- Prolonged Clotting Time Evaluation
- Thalassemias
- Thrombotic Microangiopathies – Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome
- Management of suspected reactions
- Hemolytic Anemias
- Hypercalcemia and Hypocalcemia – Vitamin D Testing
- Analytical Considerations in the Evaluation of Thyroid Function
- Hypothyroidism
- Laboratory Quality Management System Training Toolkit: Quantitative QC, Module 7
- Laboratory Quality Management System Training Toolkit: External Quality Assessment, Module 10
- Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
- Clinical Testing and Diagnosis for Hepatitis B
- Clinical Testing and Diagnosis for Tuberculosis
- Definitions of S, I and R
- Clinical Testing and Diagnosis for C. diff Infection
- Clinical Diagnosis and Testing: Alpha-gal Syndrome
- Complement Testing – Complement Deficiency and Anticomplement Therapeutic Response Monitoring
- Celiac Disease
- Allergy Blood Test
- pdf-1863.pdf
- Meeting the Biotin Challenge | myadlm.org
- PID-Nov-2015.pdf
- g089-guidance-on-reporting-of-thyroid-cytology-specimens.pdf
- Frozen Section (Fresh Tissue) - Northern Region Pathology Network Test Guide
- Acute Myeloid Leukemia Treatment (PDQ®) - NCI
- SanzMAetal2019_Blood.Managementofacutepromyelocyticleukemia-updatedrecommendationsfromanexpertpaneloftheEuropeanLeukemiaNet.pdf
- IMWG Criteria for the Diagnosis of MM | Inl Myeloma Fn
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®) - NCI
- European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021) - PMC
- phpt_concise_summary_final_020322.pdf
- AACC Guidance Document on Biotin Interference in Laboratory Tests | myadlm.org
- Diagnostic%20Algorithm%20for%20Food%20Allergy.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.